Synpeptide Co., Ltd

Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

This medication is designed to improve glycemic control in people with type 2 diabetes by targeting both the GIP and GLP-1 receptors. By stimulating these receptors, tirzepatide can increase insulin secretion and decrease glucagon secretion in a glucose-dependent manner, helping to lower blood sugar levels.

Clinical trials have shown promising results in terms of reducing HbA1c levels and body weight in individuals with type 2 diabetes. Tirzepatide is being studied in various dosages and formulations to determine its effectiveness, safety, and potential benefits for people with diabetes

NOTE: This product was prepared by chemical synthesis. Used only for research. Not for human use.